Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Teikoku’s Donepezil Tape, AbbVie’s Parkinson’s Med Up for PAFSC Review on Nov. 25
November 14, 2022
- 2 Women Die after BA.5 COVID Booster Shots: MHLW
November 14, 2022
- Kokando Told to Suspend Business for Up to 36 Days over Decades-Long Violations
November 14, 2022
- Online Submissions for Generic Approval to Start from January
November 14, 2022
- Pro-Industry Lawmakers, Govt Remain Widely Divided over Off-Year Plan
November 11, 2022
- MHLW Reserves Extra Budget to Build Gene Therapy Support Consortium
November 11, 2022
- Drug Price Negotiations by Consultants Might Violate Distribution Guidelines: Official
November 11, 2022
- Zero Coefficient Rule Hits All 10 Premium-Granted Drugs Priced by Cost Formula in FY2022
November 11, 2022
- Japan to Roll Out Moderna’s BA.4/5 Booster from Nov. 28
November 11, 2022
- Expert Panel Discussion Summary Reported to Chuikyo; Payer Rep Sees No Need for Inflation Response in Off Year
November 10, 2022
- Polivy Likely to Escape CEA-Based Price Tweaks
November 10, 2022
- MHLW Earmarks 55 Billion Yen for Domestic Antibiotic API Production: Extra Budget
November 10, 2022
- Extra Budget to Cover Enough COVID Vaccine Purchases until Next Winter
November 10, 2022
- METI Looks to Bolster Pharma Startup Ecosystem with 6-Fold Hike in Extra Budget
November 10, 2022
- Skyrizi Auto-Doser Peak Sales Put at 30-Plus Billion Yen, Mounjaro Not on Roster: November Listing
November 10, 2022
- Industry Reiterates Call for Careful Discussions on Off-Year Revision: LDP Confab
November 10, 2022
- 9-Valent HPV Vaccine Program to Start in April, Panel Seeks Early Approval of 2-Dose Regimen
November 9, 2022
- Bill to Amend Infectious Disease Act Clears Lower House
November 9, 2022
- Pharma, Payers Nudge MHLW to Speed Up Data Supply from NDB
November 9, 2022
- MOF Panel Member Calls for Drug Price Cuts to Unleash Innovation, Ease Household Burdens
November 8, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…